Artificial mammalian gene regulation networks-novel approaches for gene therapy and bioengineering.
Recently developed strategies for targeted molecular interventions in mammalian cells have created novel opportunities in biotechnological and biomedical research with huge economic and therapeutic impact: the design of mammalian cells with desired phenotypes for biopharmaceutical manufacturing, tissue engineering and gene therapy. These advances have been enabled by constructing artificial gene regulation systems with control modalities similar to those evolved in key regulatory networks of mammalian cells. This review highlights recurring cellular regulation strategies and artificial gene regulation technology currently in use for rational reprogramming of cellular key events including metabolism, growth, differentiation and cell death to achieve sophisticated bioprocess and therapeutic goals.
Institute of Biotechnology, Swiss Federal Institute of Technology, ETH Zurich ETH Hoenggerberg, HPT, Switzerland.
Wilfried
W
Weber
Martin
M
Fussenegger
D000818:Animals; D019281:Dimerization; D005786:Gene Expression Regulation; D005818:Genetic Engineering / Q000379:methods*; D015316:Genetic Therapy / Q000379:methods; D006728:Hormones / Q000096:biosynthesis / Q000235:genetics*; D006801:Humans; D020104:Immunophilins / Q000737:chemistry / Q000235:genetics; D008322:Mammals / Q000235:genetics; D008956:Models, Chemical; D008957:Models, Genetic; D012097:Repressor Proteins / Q000096:biosynthesis / Q000235:genetics*; D020123:Sirolimus / Q000737:chemistry
D006728:Hormones; D012097:Repressor Proteins; D020104:Immunophilins; D020123:Sirolimus